Skip to main content

Table 1 The antibiotic-resistanceof the two groups {carbapenem-resistant E.coli (CREC) and carbapenem-susceptible E.coli (CSEC)}

From: Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital

  Case (n = 49) Control (n = 98) p
Ampicillin 47/47 (100%) 90/96 (94%) 0.08
Piperacillin/tazobactam 38/48 (79%) 10/96 (10%) 0.00
Ampicillin/sulbactam 40/40 (100%) 75/88 (85%) 0.01
Cefoperazone/sulbactam 29/45 (64%) 13/96 (14%) 0.00
Cefazolin 42/42 (100%) 75/92 (82%) 0.00
Ceftazidime 37/39 (95%) 48/87 (55%) 0.00
Ceftriaxone 47/47 (100%) 75/97 (77%) 0.00
Cefepime 49/49 (100%) 50/96 (52%) 0.00
Cefotetan 22/31 (71%) 2/85 (2%) 0.00
Aztreonam 47/49 (96%) 62/97 (54%) 0.00
Tobramycin 26/45 (58%) 51/94 (54%) 0.69
Amikacin 3/48 (6%) 8/98 (8%) 0.68
Gentamicin 26/48 (54%) 49/98 (50%) 0.64
Ciprofloxacin 41/46 (89%) 64/96 (67%) 0.00
Levofloxacin 41/49 (84%) 60/96 (63%) 0.01
Trimethoprim + sulfamethoxaz ole 36/49 (73%) 58/96 (60%) 0.05
Nitrofurantoin 18/44 (41%) 20/98 (20%) 0.01
  1. NOTE. Categorical variables are no/total no (%), case is carbapenem-resistant E.coli (CREC), control is carbapenem-susceptible E.coli (CSEC)